Cyclo Therapeutics Granted European Patent for Alzheimer's Treatment

Cyclo Therapeutics, Inc. (Nasdaq: CYTH), a clinical-stage biotechnology company, announced a significant development in its pursuit to create transformative treatments for diseases. The European Patent Office has decided to grant the company’s European patent application No. 19805439.7, titled "Methods for Treating Alzheimer’s Disease," under European patent number 3873604B. The formal announcement of this decision will be publicized on August 21, 2024, in the European Patent Bulletin 24/34, which is also the date it will become effective.

N. Scott Fine, the CEO of Cyclo Therapeutics, underscored the importance of this milestone. He emphasized that the granting of this European patent is a crucial achievement for the company’s Alzheimer’s disease initiatives and adds significant value to their patent portfolio. Fine expressed optimism about the potential impact of Cyclo Therapeutics’ Trappsol® Cyclo™ in addressing the urgent need for innovative therapies for early-onset Alzheimer’s disease.

Cyclo Therapeutics, Inc. is focused on the development of groundbreaking medical treatments through scientific research and innovation. The company’s flagship product, Trappsol® Cyclo™, has been designated as an orphan drug in both the United States and Europe. Currently, Trappsol® Cyclo™ is undergoing four formal clinical trials targeting Niemann-Pick Disease Type C, a rare and deadly genetic condition. The specific clinical trials are registered under the identifiers NCT02939547, NCT02912793, NCT03893071, and NCT04860960 on ClinicalTrials.gov.

Additionally, Cyclo Therapeutics is conducting a Phase 2b clinical trial to explore the efficacy of Trappsol® Cyclo™ administered intravenously in early Alzheimer’s disease patients, under the identifier NCT05607615. This trial is a follow-up to promising results obtained from an Expanded Access program for Alzheimer’s disease, registered as NCT03624842. The company is also exploring other potential applications for the active ingredient in Trappsol® Cyclo™.

Cyclo Therapeutics continues to prioritize the expansion of its research and development efforts to bring new therapeutic solutions to patients and families affected by debilitating diseases. The successful acquisition of the European patent is expected to bolster the company’s efforts in Alzheimer's research, providing a foundation for future clinical advancements and potential market approvals.

In summary, Cyclo Therapeutics, Inc. is making notable progress in its mission to develop life-changing medical treatments. The company’s recent success in securing a European patent for its Alzheimer’s disease treatment methods marks a significant step forward. With a robust pipeline of clinical trials and ongoing research efforts, Cyclo Therapeutics remains committed to delivering innovative solutions to those in need.